ZYVOX(R) demonstrates high success rate for patients who develop MRSA surgical site infections
New York, Dec. 15, 2004 Surgical patients treated with Pfizer's novel antibiotic ZYVOX (linezolid; injection, tablets, and for oral suspension) had a significantly higher rate of microbiologic success (documented or presumed eradication) than those treated with intravenous (IV) vancomycin for surgical site infections (SSIs) caused by methicillin-resistant Staphylococcus aureus (MRSA), according...Pfizer's ZYVOX(TM) more effective than vancomycin in treating complicated SSTIs caused by MRSA
San Diego, October 10, 2003 Clinical cure rates were significantly better in patients treated with Pfizer's antibiotic ZYVOX was as effective as all comparators. In addition, ZYVOX shortened the average duration of IV treatment by up to 10 days and reduced patients' hospital stays by more...